Moderna Shares Plunge 18% After Melanoma Vaccine Data Leak
Moderna shares fell about 18% after leaked trial data for its melanoma vaccine fell short of elevated Wall Street expectations. The data had been slated for announcement over the weekend.
Story updates
09:11:36 PM UTC
SquawkNews
WASHINGTON (dpa-AFX) - Moderna, Inc (MRNA) shares suffered their steepest decline since August after leaked late-stage trial results for its personalized melanoma vaccine showed a smaller risk reduction than an earlier study.The stock fell as much as 26 percent before closing at $202.63, down $43.1…
Moderna (MRNA) shares fell about 18% on Thursday after leaked trial data for its melanoma vaccine fell short of elevated Wall Street expectations. The results had been scheduled for announcement over the weekend. In August, Moderna said the late-stage trial of its cancer vaccine intismeran…